Neuron
These Voices celebrate 30 years of Neuron. Around the same time Neuron was born, visually induced neuronal gamma-band synchronization was discovered and studied by Charles Gray, Andreas Engel, Peter Kö nig, and Wolf Singer. When I joined the lab in 1993 as a PhD student, the function-and even the existence-of gamma was vigorously debated in the field. For PhD students starting in 2019, this might be hard to believe. Today, the scientific community generally embraces the notion that gamma is a physiological fact, and a growing majority is convinced that neuronal synchronization in the gamma band and in other characteristic frequency bands plays functional roles for cognition. Neuronal synchronization likely affects both the sensitivity of a neuronal group to its synaptic inputs and the effectivity of its outputs. Thus, neuronal synchronization is an emergent cooperative dynamic that itself has causal consequences, and this concept has fascinated me for my own 25 years in neuroscience so far. Yet crucial questions remain. How is gamma modulated by top-down processes? How do different rhythms interact mechanistically? Today, we can investigate this better than ever. Flexible multicontact probes allow chronic simultaneous recordings from thousands of sites distributed across the brain of behaving animals, and optogenetics enables real-time closed-loop control. I look forward to the next 30 years of studies on rhythmic neuronal synchronization and its coverage in Neuron.
Toward Noninvasive Deep Brain Stimulation

Viviana Gradinaru
Caltech Modulating brain circuits in behaving animals via optogenetics or chemogenetics is now commonplace for studying brain circuitry. However, optogenetics requires surgical implantation of optical fibers to overcome poor tissue penetration by visible light. DREADDs, on the other hand, are gated by small molecules that can cross the blood-brain barrier (BBB) and hence reach the brain after systemic injection, providing minimally invasive neuromodulation across large brain volumes. Even with DREADDs, the actuator still needs to be delivered, usually by invasive stereotaxic injections resulting in limited and non-uniform spread. Furthermore, some areas are very difficult to target surgically because of the depth, the location, or the uneven geometry of the target structure. Recently developed viral-vector screening methods (e.g., CREATE) to identify capsids capable of crossing the BBB can help address this limitation. These novel capsids enable noninvasive brain-wide transduction in adult mice and rats after systemic delivery and sparse stochastic Golgi-like genetic labeling for morphological assessment. Such viral vector technologies can provide solutions to the challenge of noninvasive and circuit-or cell-type-selective delivery of sensors and actuators to the CNS in transgenic and non-transgenic animals. Together with synergistic developments in actuators, systemic adeno-associated virus will allow researchers to modulate defined cell types and circuits across multiple deepbrain structures in a minimally invasive manner and test the behavioral effects of this modulation in animal models.
Erstwhile Lost in Translation
Christian L€ uscher
University of Geneva
At the interface of basic and applied neuroscience, ''translation'' has become a central theme in my research. This was not always the case. While attending medical school, I studied basic phenomena, such as action potential propagation and synaptic transmission in brain slices. A mechanistic understanding of neurological and psychiatric diseases seemed impossible due to a paucity of experimental tools to establish causality for brain circuit function. This has fundamentally changed over the last decade with the advent of genetically encoded probes. We can now ''monitor and manipulate'' brain activity with cellular resolution. Sophisticated experimental designs probe circuit function in behavior with unprecedented precision but also make us realize that we are far from a complete understanding of the brain's complexity. Nonetheless, I believe that we should not delay investigating how our current knowledge might be used to develop therapies. Personally, I aim at designing deep-brain stimulation protocols for humans based on optogenetics in animals to overcome the dilemmas of non-specific pharmacology. Though, we must remain humble, today's scientists will only solve a handful of problems at best, passing on the bulk to a next generation. Therefore, to advance translation, it is preeminent to train young scientists. This is not only a prerequisite for neuroscience's bright future; patients suffering from brain diseases demand it.
